Johnson & Johnson $JNJ Shares Bought by Pinnacle Financial Partners Inc

Pinnacle Financial Partners Inc increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 16.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 209,915 shares of the company’s stock after acquiring an additional 28,997 shares during the quarter. Johnson & Johnson makes up approximately 0.9% of Pinnacle Financial Partners Inc’s holdings, making the stock its 21st biggest holding. Pinnacle Financial Partners Inc’s holdings in Johnson & Johnson were worth $38,923,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in JNJ. Evolution Wealth Management Inc. purchased a new stake in Johnson & Johnson in the 2nd quarter valued at about $27,000. Clayton Financial Group LLC acquired a new stake in shares of Johnson & Johnson in the third quarter worth approximately $28,000. Semmax Financial Advisors Inc. increased its position in Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after purchasing an additional 72 shares during the last quarter. GFG Capital LLC acquired a new position in Johnson & Johnson during the second quarter worth approximately $35,000. Finally, Signature Resources Capital Management LLC boosted its holdings in shares of Johnson & Johnson by 262.9% in the 3rd quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock valued at $47,000 after purchasing an additional 184 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on JNJ. Wolfe Research upped their price objective on Johnson & Johnson from $225.00 to $240.00 and gave the stock an “outperform” rating in a report on Monday, January 5th. Daiwa America upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. The Goldman Sachs Group boosted their target price on Johnson & Johnson from $213.00 to $240.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Finally, Citigroup raised their price target on shares of Johnson & Johnson from $215.00 to $232.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Four research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $213.33.

Johnson & Johnson Price Performance

JNJ stock opened at $218.81 on Tuesday. The firm has a market cap of $527.18 billion, a P/E ratio of 21.12, a price-to-earnings-growth ratio of 2.25 and a beta of 0.34. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $220.11. The stock has a 50-day simple moving average of $206.43 and a 200-day simple moving average of $187.62.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s payout ratio is presently 50.19%.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analysts are becoming more constructive on JNJ heading into 2026, citing improving fundamentals and durable cash flow that support the dividend and valuation. Analysts Turn More Constructive on Johnson & Johnson
• Positive Sentiment: Zacks highlights J&J alongside other large names and notes strong pharma and MedTech momentum, which could underpin revenue growth and investor confidence heading into earnings. Zacks Investment Ideas feature highlights
• Positive Sentiment: JNJ continues to be recommended as a dividend holding in retail investor lists, reinforcing demand from income‑oriented investors given its yield and payout consistency. 3 Dividend Stocks to Own
• Neutral Sentiment: Multiple pre‑earnings analyst pieces (TipRanks, Zacks) note JNJ’s Q4 revenue expectations (~$24.16B, roughly +7% YoY) and discuss positioning strategies for investors who want exposure but want to limit risk ahead of the print. Is JNJ Stock a Buy Ahead of Q4?
• Neutral Sentiment: Zacks’ Q&A on buy/hold/sell frames JNJ as a mixed case: strong product momentum but headline risk into the report — useful context but not a direct catalyst. Should You Buy, Sell or Hold J&J Ahead of Q4?
• Negative Sentiment: Seeking Alpha warns J&J is tempering expectations after a sizable 2025 downgrade, highlighting margin and growth pressures that could weigh on sentiment if management echoes lowered guidance. Tempering Expectations After A Massive 2025
• Negative Sentiment: Zacks and other previews call out near‑term headwinds: Stelara biosimilar competition and China market pressures that could blunt top‑line growth and weigh on the print. Buy/Sell/Hold Preview
• Negative Sentiment: Bank of America maintained a Hold rating, signaling limited near‑term upside in analyst coverage and possibly contributing to cautious positioning. Bank of America Sticks to Hold

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.